The OncoAlert🚨Newsletter Covering March 20-26, 2026 REGISTER TO GET IT 👉 https://t.co/foapk6qLux or https://t.co/yzt83gqQkF 🚨 This week’s Spotlight is all about trials making waves 🔵 CALYPSO – Savolitinib + durvalumab in papillary renal cancer 🧬 TAILORx – AI validation for

OncoAlert 🚨 Coverage of DAY ONE of #EBCC15 The impact of polyurethane coated implants on the risk of capsular contracture after immediate prepectoral breast reconstruction in the setting of postmastectomy radiotherapy: the OPBC-09 PRExRT study presented by Dr. Kerstin Wimmer

⚖️ Debate at #EBCC15 Take part in this lively debate between high-level participants on: AI in mammography screening programs: Replacing human readings. #BreastCancer #AI #Imaging #Oncology @OncoAlert

⚖️ Debate ongoing at #EBCC15 Take part in this lively debate between high-level participants on: Trastuzumab Deruxtecan in ER+ metastatic breast cancer after 1-2 lines of endocrine therapy. #BreastCancer #Oncology @OncoAlert

📌 Debate: Targeted Axillary Dissection: Future Standard or Transitional Tool? 👉🏻Arguments for TAD as future standard 🎙️ Thorsten Kühn at #EBCC15 Chaired by @itrisabel @FioriPoulakaki @OncoAlert #OncoAlertAF

🫁 ALK+ NSCLC update by @bensolomon1 at #ELCC26: from TKIs to immune strategies ▪️ ALK TKIs → unprecedented outcomes (CROWN 👑) ▪️ Novel TKIs (e.g. NVL-655) → tackling compound resistance + CNS disease ▪️ ALK vaccines? Early signals of synergy with ICIs From fusion to

High ORR (88.3%) with a novel ADC + PD-1 combo in frontline ES-SCLC #ELCC26 Phase II (408O): iza-bren (EGFR x HER3 bispecific ADC) + serplulimab in treatment-naive ES-SCLC Study population 77 evaluable pts, China Median follow-up: 10.5 months Trial arms 💉 Iza-bren 2.5 mg/kg +

📌Debate: Targeted Axillary Dissection: Future Standard or Transitional Tool? “Arguments for TAD as transitional tool” Marjolein Smidt at #EBCC15 ✨ Chaired by @itrisabel and @FioriPoulakaki ✨ @OncoAlert #OncoAlertAF

RAPCHEM study (Dr Fleur Mauritz): tailoring #radiotherapy by post-chemo nodal response keeps 10-yr LRR at just 2.9% in 848 pts 🇳🇱 Awarded #EBCC15 Strong signal that risk-adapted RT can reduce overtreatment without compromising outcomes @OncoAlert #OncoAlert #BreastCancer

Kicking off #ELCC26 with @APassaroMD opening the stage, setting the tone on lung cancer! Let’s see if we can Passaro the limits of what we know 🚀 Follow @OncoAlert to keep up with #ELCC26 🫁

Keynote by @fred_hirsch at #ELCC26: biomarkers in the ADC era! 🎯 ▪️ADCs expanding → HER2, TROP2, MET ▪️Selection evolving → from all-comers → biology-driven ▪️Beyond expression → internalization & payload matter No biomarker, no direction. ADC = A Decision Challenge 🎯

How I think about 1st line HER2+ Metastatic Breast Cancer. Decision 1: THP versus T-DXd + P Decision 2: Maintenance based on receptor status @OncoAlert #bcsm

Nice talk about future of ADC in Lung cancer. Protein expression is not born with cut offs 🙂 Great 👍 opening to #elcc2026 @myESMO @Tony_Calles @Alfdoc2 @APassaroMD @FordePatrick @DrewMoghanaki @OncoAlert

📌 Plenary session 🔛 “Tumour heterogeneity, plasticity and progression” ✨ @CedricBlanpain 👏🏻 at #EBCC15 Chaired by @MIgnatiadis @OncoAlert #OncoAlertAF

OncoAlert 🚨 Coverage of DAY ONE of #EBCC15 What matters most: A Q-methodology study of the viewpoints of women diagnosed with a BRCA gene mutation on person-centred care Presented by Leonie Witte This mixed-methods Q-study explored what person-centred care (PCC) means to

OncoAlert 🚨 Coverage of DAY ONE of #EBCC15 Distinguishing True Recurrence from Second Primary Breast Cancer by Molecular Clonality Analysis presented by Tess Snellen This retrospective study from the Netherlands Cancer Institute evaluates the use of molecular clonality

📌 Understanding of novel targets✨ great presentation by @DarjaMolan at #EBCC15 @OncoAlert #OncoAlertAF #personalisedcare #multidisciplinaryteamsupport @EuropaDonnaSLO

✨ At #EBCC15 the Arts & Humanities Award was presented to Stanislava Zeitoun (ED Slovakia) Her campaign reimagines breast self-examination through awareness, self-love and mindful connection to the body, without fear. @BreastEuropean @OncoAlert

#EBCC15 has officially opened in Barcelona 🇪🇸 1,450+ participants, 126 speakers, 81 countries: a global community shaping the future of breast cancer care. A unique conference where progress is not only scientific, but also human. @BreastEuropean @OncoAlert

APOLOGIES ON THE POST: THIS POST IS REPORTING RAPCHEM Study Presented by Dr Fleur Mauritz A ten-year study shows that tailoring radiotherapy after chemotherapy and surgery to a patient’s individual risk keeps breast cancer recurrence rates very low while potentially reducing